Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
Proposed combination enhances Pfizer’s position as a leading company in oncology
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
Subscribe To Our Newsletter & Stay Updated
